Stereotaxis (NYSEAMERICAN:STXS) Releases Quarterly Earnings Results, Hits Expectations

Stereotaxis (NYSEAMERICAN:STXS) issued its earnings results on Tuesday. The company reported ($0.05) earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of ($0.05), FiscalAI reports. The business had revenue of $8.93 million for the quarter, compared to analysts’ expectations of $9.60 million. Stereotaxis had a negative return on equity of 130.84% and a negative net margin of 74.24%.

Stereotaxis Price Performance

NYSEAMERICAN STXS traded down $0.11 on Tuesday, hitting $1.03. 733,072 shares of the stock were exchanged, compared to its average volume of 607,601. The company’s 50-day moving average price is $1.17 and its two-hundred day moving average price is $1.67. Stereotaxis has a 52-week low of $0.80 and a 52-week high of $2.89. The company has a market capitalization of $103.21 million, a price-to-earnings ratio of -4.29 and a beta of 1.40.

Analyst Upgrades and Downgrades

A number of research firms recently weighed in on STXS. Citizens Jmp decreased their price target on Stereotaxis from $4.00 to $3.00 and set a “market outperform” rating for the company in a research report on Thursday, August 27th. Citigroup restated an “outperform” rating on shares of Stereotaxis in a report on Thursday, August 27th. Finally, TD Cowen reduced their price objective on shares of Stereotaxis from $5.00 to $3.00 and set a “buy” rating for the company in a research note on Wednesday, August 12th. Five research analysts have rated the stock with a Buy rating. Based on data from MarketBeat.com, the stock has a consensus rating of “Buy” and a consensus target price of $3.38.

About Stereotaxis

Stereotaxis, Inc. develops robotic technologies for minimally invasive endovascular procedures, with a primary focus on cardiac electrophysiology. Its systems use magnetic navigation and specialized software to help physicians control guidewires and catheters during procedures such as the treatment of cardiac arrhythmias. The company’s product portfolio includes the Genesis Robotic Magnetic Navigation System, which is designed to provide precise catheter movement and navigation within the heart.